Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)

被引：0
|
作者：
Giagounidis, A. [1 ]
Ades, L. [2 ]
Watts, J. [3 ]
Radinoff, A. [4 ]
Arnan Sangerman, M. [5 ]
Cerrano, M. [6 ]
Font Lopez, P. [7 ]
Zeidner, J. [8 ]
Diez Campelo, M. [9 ,10 ]
Graux, C. [11 ]
Liesveld, J. [12 ]
Selleslag, D. [13 ]
Tzvetkov, N. [14 ]
Fram, R. J. [15 ]
Zhao, D. [15 ]
Bell, J. [15 ]
Friedlander, S. [15 ]
Faller, D. V. [15 ]
Sekeres, M. A. [16 ]
机构：
[1] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany
[2] Hop St Louis, Paris, France
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Hosp Sveti Ivan Rislki, Sofia, Bulgaria
[5] Inst Catala Oncol Inst Invest Biomed Bellvitge ID, Barcelona, Spain
[6] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain
[10] Ctr Canc Res IBMCC USAL CSIC, Salamanca, Spain
[11] Catholic Univ Louvain, Ctr Hosp Univ, Namur, Belgium
[12] Univ Rochester, James P Wilmot Canc Inst, Rochester, NY 14627 USA
[13] AZ Sint Jan Brugge Oostende, Brugge, Belgium
[14] MHAT Dr Georgi Stranski, Clin Haematol, Pleven, Bulgaria
[15] Millennium Pharmaceut Inc, Cambridge, MA USA
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
653
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [21] FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE
    Madry, K.
    Lis, K.
    Zurawska, J.
    Gorka, M.
    Kacprzyk, P.
    Dutka, M.
    Rodzaj, M.
    Bolkun, L.
    Krochmalczyk, D.
    Drozd-Sokolowska, J.
    Waszczuk-Gajda, A.
    Knopinska-Posluszny, W.
    Kopinska, A.
    Subocz, E.
    Masternak, A.
    Guzicka-Kazimierczak, R.
    Gil, L.
    Machowicz, R.
    Dwilewicz-Trojaczek, J.
    HAEMATOLOGICA, 2017, 102 : 490 - 490
  • [22] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
  • [23] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
    Sekeres, Mikkael A.
    Schuster, Michael W.
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [25] Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib plus Azacitidine
    Wang, Eunice
    Bell, Timothy
    Zeidan, Amer
    Bhattcharyya, Helen
    Kudla, Arthur
    Chan, Geoffrey
    Sekeres, Mikkael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S191
  • [26] A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
    Donnellan, William Bruce
    Diez-Campelo, Maria
    Heuser, Michael
    Ritchie, Ellen K.
    Skolnik, Jeffrey
    Font, Patricia
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [28] A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2014, 124 (21)
  • [29] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Breems, Dimitri
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ching, Keith
    O'Brien, Thomas
    Stampino, Corrado Gallo
    Ma, Weidong Wendy
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
  • [30] Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence
    Zeidan, Amer
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice
    Ma, Weidong
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Sekeres, Mikkael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S192
12345